Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

DiCE

- PMLiVE

Executive changes at Sanofi

Genzyme CEO Meeker becomes executive VP and Hellmann joins to lead animal health

Sanofi Israel crowdsources new diabetes app

Collaborates with online patient network Camoni

Sanofi reception

Sanofi wins Japanese approval for diabetes drug Lyxumia

Becomes first treatment of its class licensed in combination with basal insulin

- PMLiVE

Sanofi CEO Viehbacher to head EFPIA

Assumes presidency at European trade body

- PMLiVE

ADA: Sanofi eyes 2014 submissions for Lantus successor

Releases first phase III data for U300 formulation of insulin glargine

- PMLiVE

Cost deters NICE from Sanofi’s bowel cancer drug Zaltrap

Fails to win recommendation despite patient access scheme

- PMLiVE

Sanofi and AstraZeneca form cancer research alliances with non-profits

Will work respectively with Curie Institute in France and Cancer Research UK

- PMLiVE

FDA approves Sanofi’s four-in-one flu vaccine

But wants more safety data for hepatitis B vaccine from Dynavax

Sanofi reception

Sanofi gives up on iniparib and otamixaban

Drops cancer drug and anticoagulant after negative late-stage trials

- PMLiVE

A look back at Sanofi’s merger with Synthélabo

This month, in 1999: How two pharma companies came together to create a giant

Sanofi reception

Sanofi reconsiders closure plans in Toulouse after government pressure

Report says research site can remain open with minimal job losses

Sanofi reception

Sanofi plans to file JAK2 inhibitor after positive phase III

Aiming for approval in blood cancer myelofibrosis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links